Lupus: Open Access
Open Access

Clinician’s Perceptions of a CME Activity to Increase Knowledge of Vaccination in Adults with Chronic Inflammatory Conditions

Saira Z Sheikh^1,2*, Edward G A Iglesia^1,2, Matthew Underwood³, Shruti Saxena-Beem¹ and Mildred Kwan^{1,2 *}Correspondence: MD. Saira Z Sheikh, Thurston Arthritis Research Center, 3300 Thurston Building, CB 7280, Chapel Hill, NC 27599, USA, Tel: 919-966-0545, Fax: 919-966-1739, Email:

Author info »

Introduction

Patients with systemic lupus erythematosus (SLE), a chronic inflammatory disease, are at higher risk for infections compared to the general population, and complications from these infections are more frequent in this patient population [1-3]. Patients with SLE have a 13-fold higher risk of developing invasive pneumococcal infection compared with general population [4]. The increased risk of infection in chronic inflammatory disease is attributable both to an altered immune response associated with the immune condition itself and to the immunosuppressive treatments required to control the underlying inflammatory condition [5].

This greater susceptibility to infection is precisely why increasing vaccine coverage in lupus patients is vital since respiratory infections from Streptococcus pneumoniae and other agents are the leading cause of serious infections in SLE [6,7] and infections still account for approximately one-third of SLE deaths despite a decreasing trend of mortality in these patients [8].

Patients with other chronic inflammatory diseases also display this higher risk for infections and more frequent complications seen in SLE patients. For example, patients with rheumatoid arthritis (RA) have a 2.75-fold increase in incidence of influenza complications compared to controls, and between 7.1 and 33.3 times the rate of invasive pneumococcal disease [3-9] In patients with asthma, a chronic inflammatory respiratory disease, influenza infection is associated with more severe and frequent viral lower respiratory tract infections, pneumonia, and secondary bacterial infections [10]

Despite the high risk of infections and complications, strong evidence of vaccine safety and efficacy, and recommendations from national organizations, vaccination rates remain suboptimal with 40% of SLE patients remaining unvaccinated against influenza, pneumonia, or both [11].

These rates are comparable with under-vaccination in patients with RA and other autoimmune conditions, ranging from 10% to 35% for influenza vaccine and 17% to 54% for pneumococcal vaccine in some studies [1,2,5,12-14]

The Centers for Disease Control (CDC) identified lack of knowledge about vaccines among adult patients and adult providers as the most substantial barrier to vaccination coverage [15] Several studies demonstrated that vaccination rates among high-risk populations were strongly associated with information received by patients from healthcare providers, underscoring the crucial role physicians have in positively influencing the vaccination behavior of their patients [1,12,16]

Based on these reports, we conducted a retrospective review of historical vaccination rates in our clinics. We used the Carolina Data Warehouse for Health to review the charts of patients with chronic rheumatic disease, as identified by ICD-9 codes for SLE, RA, psoriatic arthritis, polymyositis and dermatomyositis, who were seen at our clinics between 2010 and 2013.

We found that the rates of pneumococcal and influenza vaccination in our patients was approximately 20% and 45% respectively. Limitations include reliance on electronic logging of vaccination data which was not required at the time and usage of limited diagnosis codes as we only reviewed the rheumatology clinic. Despite these limitations, these suboptimal rates of vaccination were in line with national averages and prompted us to explore provider education as an avenue to improve vaccination coverage.

The importance of effective educational activities such as the one proposed here are highlighted by the results of studies demonstrating that vaccination rates among patients with chronic inflammatory conditions were markedly higher among those who had received information about vaccines from their healthcare provider [1-12]

For example, among 485 patients with SLE treated with immunosuppressants, lack of provider recommendation was cited as the reason for failure to receive vaccination in 55% of the 175 patients who did not receive influenza vaccine, and in 87% of the 159 patients who did not receive pneumococcal vaccine [11]

In another example, among 490 patients with rheumatic disease, those who received a recommendation for influenza vaccination by their general practitioner were significantly more likely to be vaccinated than those who did not (57% vs. 15%, adjusted odds ratio [AOR] 6.6, 95% CI 4.1–10.8). This effect was even more significant if they received a recommendation by their rheumatologist (62% vs. 19%, AOR 9.0, 95% CI 4.9–16.5).(12) Yet, only 53.6% of patients claimed to have received information regarding vaccination from one of their healthcare providers [12] In summary, most patients indicate they would get a vaccine on the advice of their physician, and the failure of physicians to recommend vaccination to those at risk is consistently cited as a primary barrier to improved uptake [5,11-13]

Therefore, educational activities that promote healthcare provider awareness about the importance of vaccinations in patients with autoimmune, immunodeficient and allergic respiratory diseases, and educate providers to recognize clinical settings in which vaccines are indicated or contraindicated may increase the rate of appropriate vaccination in these high-risk populations.

Methods

Aim

The aim of this study was to describe prescribers’ perceptions of an educational activity that was developed to increase rates of appropriate pneumococcal and influenza vaccination in adults with chronic inflammatory conditions. We were interested in the impact of the education on the knowledge and practice of providers.

Study design

An educational activity was developed incorporating concise, multimodal educational approaches (e.g., frequently asked questions, algorithms, and 4 brief case studies) in a single 8-page monograph (Appendix 1). Educational content incorporated Advisory Committee on Immunization Practices guidelines regarding annual seasonal influenza and pneumococcal vaccination [17-19]

The activity was designed to promote awareness of the importance of and outline best practices for pneumococcal and influenza vaccinations in adults with chronic inflammatory conditions, with the ultimate goal being to increase pneumococcal and influenza rates in these patient populations.

This activity was disseminated nationally in online and print formats and presented in a live, interactive “in-house” event at a single site. The presentation slides for the live format were developed from the monograph and this format is comparable to the online/print format.

Consent

The institutional review board determined that the study was exempt from review, and that individual consent from participants was waived for data collection and/or publishing of de-identified, pooled data that was collected through surveys. Consent for completion of surveys was implied as participants had the option to voluntarily complete the surveys or decline participation. No patients were involved in this activity.

Participants

In this pilot study, the printed monograph of this educational activity and the digital copy available online (which were approved for continuing medical education credit by the Accreditation Council for Continuing Medical Education [ACCME]) were made available to allergists/immunologists, rheumatologists, fellows, students and other medical professionals via the American Academy of Allergy, Asthma & Immunology (AAAAI) website and mailings.

AAAAI members interested in completing the CME activity were able to access the monograph from October 15, 2016 and October 14, 2018 and review the educational activity at their convenience.

Additionally, healthcare providers in our single academic rheumatology, allergy, and immunology division participated in the educational activity in a 1 hour, live, interactive “in-house” event. The information on the monograph was adapted into PowerPoint slides with the addition of the results of the review of historical vaccination rates in our clinics as well as one more case study reflecting the patient population most frequently seen in our clinics.

Assessments

Participants completed a course evaluation (Appendix 2) to rate their ability to perform the two defined learning objectives for the educational activity upon completion of the activity, and their perception of the quality of the activity and relevance to their practice. Ratings were based on a 5-point Likert scale for both the ability to perform learning objectives (1=not confident, 5=able to demonstrate) and for perceptions of quality and relevance (Excellent to Poor).

Participants were also asked whether they planned to make changes to their practice (patient care, research, or teaching) based on knowledge and skills gained in completing educational activity. In addition, participants completed an online 10- question, multiple-choice and true/false post-test after completing the educational activity via print or online. For those participating in the live interactive activity, provider knowledge before and after the activity was assessed via a pre-test and posttest utilizing the same 10-question test completed after the online/print activity.

Statistical analysis

Descriptive statistics were used to assess confidence in vaccination practices and perception of the activity as measured by course evaluation responses. Paired t-test was used to evaluate pre- and post-activity knowledge among the providers who completed a pre- and post-test during the live, interactive format of the activity.

Results

308 participants completed the activity via print or online and took the post-test. The vast majority were physicians, although several physician assistants, nurse practitioners, and nurses completed the activity as well.

The course evaluation was completed by 257 of these participants, which represents an 83% response rate. Among these responders, 93% (n=240) indicated confidence in applying current guidelines for pneumococcal and influenza vaccination and recognizing the clinical settings in which these vaccines are indicated or contraindicated, after completing the activity, defined as a response of ‘4’ or ‘5’ on the Likert scale for ability to perform learning objectives (Figure 1A)

Figure 1a. Confidence of participants in their ability to perform learning objectives after completion of the educational activity (print or online)

Based on the same Likert scale assessment, 93% (n=240) of respondents indicated confidence in their understanding of the importance of vaccinations in patients with autoimmune disease, including those receiving immunosuppressive therapy, and with chronic inflammatory conditions (Figure 1A).

The majority of respondents perceived the quality of the content (87%, n=223) and format (88%, n=226) of the educational activity to be very good to excellent (Figure 1B)

Figure 1b. Participant’s perception of the quality of the content and format of the educational activity (print or online)

89% (n=229) of respondents believed the content was very relevant to their practice. 55% (n=142) of respondents planned to change their practice based on knowledge and skills gained in completing the educational activity. Among those who did not plan to change their practice (n=82), 68% felt that their current practice behaviors were reinforced by the activity.

The most common request for further information among respondents was regarding vaccinations in patients undergoing immunoglobulin replacement.

21 participants took part in the live, interactive educational activity, and took the pre- and post-tests assessing knowledge. The mean scores on the pre- and post-tests were 75% (SD 11.6%, 95% CI 70-80%) and 89% (SD 11.1%, 95% CI 85-95%; p=.0001 vs. pre-test score), respectively, demonstrating that knowledge was significantly increased after completing the activity (Figure 1C).

Figure 1c. Vaccine knowledge among participants before and after the live, interactive educational activity.

Learning objective 1

Understand the importance of vaccinations in patients with autoimmune disease, with autoimmune disease on immunosuppressive therapy, and with chronic inflammatory conditions.

Learning objective 2

Apply the current guidelines for pneumococcal and influenza vaccinations and recognize the clinical settings in which these vaccines are indicated or contraindicated.

Discussion

The online/print format comprised of a post-test only evaluation of measures and limited our ability to quantify the impact of the educational activity on clinical practice. We used a pre-test/post-test format for the live, interactive format of the activity in order to more specifically assess impact. Additional limitations of our study for all formats of the educational activity include the inability to fully assess potential degree of selection bias given limited baseline characteristic data for participants, and the fact that the knowledge questions were not previously validated.

Clinician education is a strategy previously associated with improvements in influenza and pneumococcal vaccination rates [2,20]. The activity assessed here promotes healthcare provider awareness about the importance of vaccinations in patients with chronic inflammatory diseases and educates providers to recognize clinical settings in which particular vaccines are indicated or contraindicated. It has the flexibility to be accessed in various formats, and should be incorporated into quality improvement endeavors to increase vaccination rates among patients with chronic inflammatory conditions.

Conclusions

In conclusion, this educational activity was effective in increasing clinicians ’ understanding of the importance of vaccinations in adults with chronic inflammatory conditions. It also improved their confidence in applying the current guidelines for pneumococcal and influenza vaccinations in these high-risk populations, and in recognizing the clinical settings in which these vaccines are indicated or contraindicated.

Acknowledgment

The authors thank Angela Cimmino, Pharm.D for the editorial assistance provided.

Conflict of Interest

Dr. Saira Sheikh has served as a consultant on an Advisory Board for GlaxoSmithKline. Dr. Edward G.A. Iglesia, Matthew Underwood, Shruti Saxena-Beem and Dr. Mildred Kwan have declared no conflicts of interest.

Funding

The Fund for Excellence in Lupus and Sjogren ’ s at the University of North Carolina at Chapel Hill ’ s Thurston Arthritis Research Center.

Irb Approval

The University of North Carolina at Chapel Hill institutional review board determined that the study (Protocol # 16-1898) was exempt from review, and that individual consent from participants was waived for data collection and/or publishing of de-identified, pooled data that was collected through surveys.

References

1. Brocq O, Acquacalda E, Berthier F, Albert C, Bolla G, Millasseau E, et al. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic nflammatory joint: A retrospective study. Joint Bone Spine. 2016;83(2):155-159.
2. Broderick R, Ventura I, Soroosh S, Franco L, Giles JT. Reducing missed opportunities for influenza vaccination in patients with rheumatoid arthritis: Evaluation of a multisystem intervention. J Rheumatol. 2018;45(9):1220-1228.
3. Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2018;36(2):317-328.
4. Luijten RK, Cuppen BV, Bijlsma JW, Derksen RH. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus. 2014;23(14):1512-1516.
5. McCarthy EM, Azeez MA, Fitzpatrick FM, Donnelly S. Knowledge, attitudes, and clinical practice of rheumatologists in vaccination of the at-risk rheumatology patient population. J Clin Rheumatol. 2012;18(5):237-241.
6. Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: Hospitalisations and mortality. Lupus. 2009;18(8):682-689.
7. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60(12):1141-1144.
8. Abu-Shakra M. Do Improved Survival Rates of Patients with Systemic Lupus Erythematosus Reflect a Global Trend? J Rheumatol. 2008;35(10):1906-1908.
9. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.
10. Greenhawt MJ. Influenza vaccination in asthmatic patients. J Allergy Clin Immunol. 2014;133(4):1233-1234.
11. Lawson EF, Trupin L, Yelin EH, Yazdany J. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2015;44(6):666-671.
12. Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, et al. Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. Vaccine. 2018;36(32):4875-4879.
13. Nguyen M, Lindegaard H, Hendricks O, Friis-Moller N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017;46(6):446-453.
14. Sandler DS, Ruderman EM, Brown T, Lee JY, Mixon A, et al. Understanding vaccination rates and attitudes among patients with rheumatoid arthritis. Am J Manag Care. 2016;22(3):161-167.
15. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(2):1-64.
16. Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. Dig Liver Dis. 2018;50(6):563-567.
17. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
18. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65(5):1-54.
19. Kobayashi M, Bennett NM, Gierke R, Almendares O,  Moore MR, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944-947.
20. Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, Johnson JA. Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: A systematic review and meta-analysis. Ann Fam Med. 2012;10(6):538-546.